Navigation Links
Calpis' AmealPeptide lowers blood pressure in 2 placebo-controlled trials
Date:5/16/2008

New Orleans, LA, May 16 Two new clinical trials presented by Calpis Co., Ltd. at the American Society of Hypertension (ASH) Twenty-Third Annual Scientific Meeting and Exposition (ASH 2008) in New Orleans show that the milk-derived dietary supplement AmealPeptide reduces blood pressure in hypertensive patients. The studies, called AHEAD (Achieve Hypertension Efficacy with AmealPeptide Dietary Supplement ) II, and the PROBE (A Prospective, Two-phase Randomized, Open-Label, Blinded End-Point) Dose Response Study confirmed the safety and efficacy of AmealPeptide for patients with Stage I and Stage II hypertension.

The AHEAD II study found that the milk-based product produced a mean drop in daytime, ambulatory systolic blood pressure of 3.6 mmHg for the active group after 6 weeks of treatment. The change was both statistically and clinically significant. According to JNC 7 (The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure), just a 2 mmHg reduction in systolic blood pressure results in a 6% reduction in mortality due to stroke and a 4% reduction in mortality due to coronary heart disease (CHD).

Results of the PROBE study showed AmealPeptide to have a dose dependent blood pressure lowering trend and a reduction of daytime ambulatory blood pressure of 7.6 mmHg ( 8.7) in the 75 mg a day group and also a significant reduction in 24-hr systolic blood pressure in the same group of 6.2 mmHg ( 8.4) from the baseline after 8 weeks of treatment. A lower dose of 5 mg a day of AmealPeptide also showed blood pressure lowering effect.

Its very exciting to see blood pressure reductions achieved by the food derived substance, AmealPeptide stated Joel Neutel, MD, Associate Clinical Professor of Medicine at the University of California, Irvine and a specialist in clinical hypertension of the American Society of Hypertension. With hypertension and prehypertension on the rise, physicians and patients need as many effective tools as possible for the management of this condition, he concluded.

The AHEAD II study enrolled 81 newly diagnosed stage I and stage II hypertensives. All subjects had a mean daytime systolic blood pressure between 140 mmHg and 179 mmHg at the start of the trial. Fifty-two received 75 mg of AmealPeptide twice a day for 6 weeks, while 29 received a placebo. The PROBE study enrolled 59 diagnosed stage I and stage II hypertensives who were not taking any antihypertensive medications or who were uncontrolled on antihypertensive therapy. All subjects had a mean seated systolic blood pressure between 150 mmHg and 179 mmHg and a mean daytime systolic blood pressure between 140 mmHg and 179 mmHg at the start of the trial. All enrolled received AmealPeptide (5mg, 15mg, 50mg, 75mg a day or 75mg twice a day) or placebo.

"Calpis takes pride in conducting research that holds up under serious scientific scrutiny," said Craig Tillman, Vice President of Sales & Marketing, Calpis USA, Inc. "This new data confirms that AmealPeptide can make a difference in those with elevated blood pressure."

The AHEAD II and PROBE data builds on more than 11 previous Japanese placebo-controlled clinical studies showing that AmealPeptide lowers blood pressure in hypertensives and prehypertensives without producing the side effects that can be associated with drug therapy.


'/>"/>

Contact: Maureen Kiggins
mkiggins@optonline.net
516-676-6774
HCIL
Source:Eurekalert

Related medicine news :

1. Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes
2. Aspirin at Bedtime Lowers Blood Pressure
3. The Childrens Heart Foundation Teams Up With ProFlowers(R) to Raise Awareness and Funding for the Leading Birth Defect in America
4. 2-drug blood pressure therapy lowers cardiovascular risk
5. Hospital Testing for Drug-Resistant Infections Dramatically Lowers Mortality Rates and Costs
6. Galichia Heart Hospital Lowers Cost of Bypass to $10K
7. Aggressive Diabetes Therapy Lowers Death Risk, Study Finds
8. Major Community Health Organization Lowers TCO with Ericoms Alternative to Citrix
9. Anti-Inflammatory Drug Improves Glycemia, Lowers Inflammation in Obese, Young Adults
10. Daily exercise dramatically lowers mens death rates
11. Better access to cool caps improves outcomes, lowers cost of treating asphyxia in newborns
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2017)... ... ... The Los Angeles leg of the US movie premier of the Man in the Camo ... the Clive Davis Theater inside the Grammy Museum Located in downtown Los Angeles in the ... Welsh rock musician, Mike Peters (of The Alarm), his rise to fame, battle with cancer ...
(Date:7/27/2017)... ... 27, 2017 , ... Cremations recently surpassed traditional burials for the first time ... expected to continue with over 70% of Americans projected to choose cremation by 2030. ... that enable families to celebrate the life of a lost loved one in different ...
(Date:7/26/2017)... ... ... greater Bay Area roller derby leagues are partnering with Brown Paper Tickets and the American ... blood drives in California, beginning July 29. Make ‘Em Bleed roller derby blood drives have ... have helped to save up to 2700 lives. , “The Make ‘Em Bleed blood drives ...
(Date:7/26/2017)... Maryland (PRWEB) , ... July ... ... Society for Pharmaceutical Engineering (ISPE) will host its 2017 Process Validation ... These concurrent events offer comprehensive solutions to process validation lifecycle challenges faced ...
(Date:7/26/2017)... (PRWEB) , ... July 26, 2017 , ... ... dogs and cats has opened in Jupiter. The state of the art ... and class leading treatments with a goal of providing heart patients longer lives. ...
Breaking Medicine News(10 mins):
(Date:7/25/2017)... and CAMBRIDGE, Massachusetts , July 25, ... in repurposing drugs to treat rare nervous system diseases, has ... clinically develop and market the drug SOM0226 against transthyretin amyloidosis ... achieved very promising results in a Phase 2 study conducted ... new office in the United States ...
(Date:7/21/2017)... and RESEARCH TRIANGLE PARK, N.C. ... (NASDAQ: UTHR ) announced today that it ... the market opens on Thursday, July 27, 2017. ... a teleconference on Thursday, July 27, 2017, at 9:00 ... 1-877-351-5881, with international callers dialing 1-970-315-0533.  A rebroadcast of ...
(Date:7/17/2017)... Fla. , July 17, 2017  MedX Holdings, ... branded medical testing, strengthening and rehabilitation equipment, today announced ... Machine Program. MedX is considered the gold standard for ... leader in specialized medical strengthening equipment. ... a lease with the physician or practice who prescribe ...
Breaking Medicine Technology: